Zimmer Holdings (NYSE:ZMH) specializes in providing knee and hip replacements to patients across the globe. Close to a decade ago, the business was growing briskly and demographic trends were thought to be on Zimmer's side. The aging of the baby boomers in the United States and older individuals abroad were supposed to power Zimmer well into this century. Unfortunately, the latest recession has slowed Zimmer's prospects and the company has yet to return to its former glory.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers

Recent Results and Outlook
Reported second quarter sales fell 1.1% to $1.1 billion. Backing out negative currency fluctuations, which stemmed from a stronger dollar that reduced reported overseas sales, the top line advanced a more respectable 1.8%. Cost cutting moves (the company is referring to them as "commercial and operational excellence programs") and backing out the foreign exchange changes resulted in recurring profit growth of 10.7% to $235.6 million, or $1.34 per diluted share.

Looking at the major product areas, reported knee and hip replacement sales fell 2% and 1%, respectively. These make up the vast majority of the total company top line. Smaller units, including trauma and surgical, grew 7% each, but were offset by an 8% decline in dental and 7% drop in spine. By region, both the Americas and Asia Pacific regions grew 1%, but were partially offset by a 6% decline in Europe.

For the full year, Zimmer expects modest sales growth between 2.5% and 3.5%, which ignores currency fluctuations. Backing out the fluctuations, reported growth should come in between zero and 1.5%. Earnings expectations are in a range of $5.25 and $5.35 per diluted share on an adjusted basis, and $4.75 to $4.85 on a reported basis.

SEE: A Primer On Currency Regimes

The Bottom Line
Zimmer has continued to struggle to grow since the Great Recession. Its track record over the past decade looks impressive. During this period, average annual sales growth has been above 14% and profits have advanced 18% each year over this time frame. However, this includes the past five years of results that have seen sales growth average less than 5% and earnings grow less than 3.5%.

Zimmer has turned to cost cutting to keep total profit growth moving positively forward, but doesn't appear to have any answers to returning to robust sales growth. During the earnings conference call, it spoke of solid results in international markets, but Europe has been a real drag and could continue to struggle for some time.

SEE: Great Expectations: Forecasting Sales Growth

On a positive note, the forward earnings multiple of just over 11 leaves room for upside, should growth trends start to perk up. However, rival Stryker (NYSE:SYK) has been able to grow faster in recent years and trades at less than 13 times forward expectations, which is also quite reasonable. Other firms operating in the medical device space, including Medtronic (NYSE:MDT) and St. Jude Medical (NYSE:STJ), also trade in the low teens. So do the diversified healthcare giants of Johnson & Johnson (NYSE:JNJ) and Abbott Labs (NYSE:ABT), which also operate sizable medical device units.

Add it up and there are likely better investment candidates than Zimmer in the medical field. Zimmer does again trade at a very reasonable P/E, which leaves room for upside should demand increase. There is also the potential for a buyout from a firm of Abbott or JNJ's size. It might also make sense for Stryker and Zimmer to combine forces and use any merger as an opportunity to cut corporate overhead even further.

At the time of writing, Ryan C. Fuhrmann was long shares of St. Jude but did not own shares in any other company mentioned in this article.

Related Articles
  1. Stock Analysis

    Will WYNN Continue to Rally?

    Wynn Resorts has experienced a rally recently. Will it remain a good bet?
  2. Stock Analysis

    Don't Be Fooled by the Market's Recent Rally

    The bulls won for a bit in early October, but will bears have the last laugh?
  3. Stock Analysis

    Will Twitter's Stock Find its Wings Soon?

    Twitter is an enigma to many investors, but its story is pretty straightforward.
  4. Stock Analysis

    8 Solid Utility Stocks for a Bear Market

    If you're seeking modest appreciation, generous dividend payments and resiliency, consider these eight utility stocks.
  5. Stock Analysis

    Why Phillips 66 (PSX) is a Solid Long-Term Bet

    Here's why Phillips 66 will likely remain one of the world’s largest and most profitable companies for a long time to come.
  6. Stock Analysis

    3 Resilient Oil Stocks for a Down Market

    Stuck on oil? Take a look at these six stocks—three that present risk vs. three that offer some resiliency.
  7. Economics

    Keep an Eye on These Emerging Economies

    Emerging markets have been hammered lately, but these three countries (and their large and young populations) are worth monitoring.
  8. Stock Analysis

    Is Pepsi (PEP) Still a Safe Bet?

    PepsiCo has long been known as one of the most resilient stocks throughout the broader market. Is this still the case today?
  9. Investing

    The ABCs of Bond ETF Distributions

    How do bond exchange traded fund (ETF) distributions work? It’s a question I get a lot. First, let’s explain what we mean by distributions.
  10. Stock Analysis

    The 5 Best Dividend Stocks in the Healthcare Sector

    Learn about the top five dividend stocks of companies operating in the health care sector that generate substantial cash flows to afford high payouts.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!